Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.21.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Operating expenses:        
Research and development $ 16,745 $ 7,942 $ 29,127 $ 17,451
General and administrative 6,521 3,210 11,757 7,628
Total operating expenses 23,266 11,152 40,884 25,079
Loss from operations (23,266) (11,152) (40,884) (25,079)
Interest income 44 426 111 1,265
Net loss (23,222) (10,726) (40,773) (23,814)
Other comprehensive (loss) income:        
Unrealized (loss) gain on marketable securities 7 316 (7) 106
Total other comprehensive (loss) income 7 316 (7) 106
Comprehensive loss $ (23,215) $ (10,410) $ (40,780) $ (23,708)
Basic and diluted net loss per common share $ (0.34) $ (0.16) $ (0.59) $ (0.35)
Weighted average common shares outstanding used to calculate basic and diluted net loss per common share 68,985,461 68,885,108 68,965,885 68,883,783